HealthAI - The Global Agency for Responsible AI in Health’s Post

📰 Hungarian pharmaceutical firms Richter Gedeon Nyrt. / Magyarország and BioTalentum Ltd. have achieved a significant milestone as their projects are designated "Important Projects of Common European Interest" (IPCEI) by the European Commission. This recognition underscores their commitment to innovation in healthcare. Richter's Flow-Kilo-Lab project emphasizes advanced flow chemistry technologies, offering enhanced capabilities compared to traditional methods. On the other hand, BioTalentum's Cardiabetter project aims to advance drug treatments for diabetes and heart disease. These initiatives align with European Health Union objectives, aiming to tackle diseases lacking adequate prevention or treatment options while bolstering the EU's readiness against emerging health threats 👉 https://lnkd.in/dNMEKkeg More about IPCEI 👉 https://lnkd.in/eVKzrgFu #innovation #IPCEI #pharmaceuticals #biotechnology #pharmconnect

Prof. Frederick Armah, Director of Research and Programmes, #AAU, is now presenting on the importance of collaboration in Africa's efforts to build a strong pharmaceutical workforce. Key takeaways so far: "Africa's efforts to build a strong workforce cannot proceed without deep involvement of academia. Academia can build a strong pharmaceutical workforce in Africa, driving progress towards improved health outcomes and economic growth." #USPAccess4Africa #PharmaceuticalSector #QualityStandards #SkilledWorkforce #Africa #Webinar

Ioannis Kotsiopoulos, PMP, MSc, PhD, General Manager at PIF Greece, participated in the Patients Forum 2024, where he emphasized the importance of establishing a stable, long-term agreement defined jointly by patients, industry and the government. During his speech he also highlighted the urgency of the current situation and the need to accelerate structural reforms shifting towards a collaborative model and driven by patient needs. He proposed creating a stable Pharmaceutical Policy that all stakeholders could endorse and adhere to in the years ahead. #pifgreece #patientsforum #pafo2 #predictability #transparency #accountability

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

The recent remarks by the Minister of Health Adonis Georgiadis during the 1st SFEE Summit demonstrate that the Government understands the benefits of a long term agreement between the key stakeholders that will secure equitable access to new treatments and will attract investments in Greece #newpharmaPolicy #innovation #frameworkagreement Powered by PhARMA Innovation Forum Greece (PIF)

📜 NEW PUBLICATION 📜 Jameel Institute's Sara Almeida, Katharina Hauck, Adrian Gheorghe and others, explore the value for money of medicine sampling and quality testing, using evidence from #Indonesia. Substandard and falsified medicines (SFMs) are a #publichealth concern of #global importance. However, there is remarkably scarce evidence about the cost and value for money of post-market surveillance in the form of medicine sampling and quality testing to prevent and detect #SFM. 💊 This paper provides new information on the cost and value for money of medicine quality surveillance that may support planning and budgeting of the #Indonesian pharmaceutical regulator, as well as regulators and researchers more broadly, particularly in low-and-middle-income (LMIC) settings. 📈 Read the full paper here ✍ 👉 https://lnkd.in/em28JJZv

Is Nigeria's latest pharmaceutical policy a game changer or just a temporary fix? If you missed our analysis on this matter, now's the time to catch up. In 𝗧𝗵𝗲 𝗣𝗼𝗹𝗶𝗰𝘆 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺, a new series where we review key policies across the continent, we break down the effects of the policy on local manufacturing, employment, public health, and more. Do you think this policy will bring lasting change? Swipe through for key insights, then click the link below to read the report. https://lnkd.in/gschDtJi #PolicyVault #ThePolicyPlatform #ExecutiveOrder #PharmaceuticalPolicy #Nigeria

🚀Don't miss the 9th Annual MarketsandMarkets High Potent Medicines Conference - EU Edition - https://bit.ly/3T0mdyG ✨Discover the latest trends and insights shaping the future of this dynamic sector 💊💡In today's market, outsourcing the manufacture of highly potent compounds is becoming increasingly common. Learn why companies are making this strategic move and explore the diverse factors driving the growth of the highly potent drug market, from precision medicines to advancements in manufacturing technologies. 🤝💰Connect with industry experts and gain invaluable solutions to the challenges facing advanced high-potent medicines. With over 10 hours of dedicated networking over two days, seize the opportunity to forge meaningful connections and drive your revenue targets forward. #MedicalConferences #HealthcareInnovation #Biomarkers #CompanionDiagnostics #eMedEvents

🌟 Yesterday at Biosimilars LatAm - Europe 2024! 🌟 We had the privilege of hearing Guillermo speak at the session "Clinical Development Requirements and Guidelines for Biosimilars in Latin America." 🌱 📣 "We are at a moment where regulatory organisations are striving to avoid animal use, not only because it is costly but also because there is considerable pushback on ethical grounds, which requires us to be more creative in how we evaluate safety or move to early efficacy stages before exposure to healthy volunteers. We must begin to evaluate other alternatives that provide us with results, leaving us with enough peace of mind and confidence to proceed to human exposure." - Guillermo E. Maligne, Teva Pharmaceuticals His insights emphasize the need for innovative approaches in biosimilar development to meet ethical and practical challenges. #BiosimilarsLatAm #Europe2024 #ClinicalDevelopment #Regulation #EthicalResearch #InnovationInHealthcare #biosimilars

What is pharmaceutical innovation, and which are the challenges in Greece? How can we ensure equal #access to innovative medicines for patients in Greece? Yvoni Papastelatou, Country Lead & General Manager Specialty Care Sanofi Greece & Cyprus, in her interview at Fortune Greece outlines the importance of investing in #innovation despite the challenges and the positive impact on improving peoples’ lives, healthcare and economy. Yvoni also explains the current status in Greece and Europe and the role of the new European legislation for the future of innovation.  Read the full interview here: https://lnkd.in/dDsa7dkA #SanofiGreece #WeNeverSettle #FortuneGreece